Study of PDS0101 and Pembrolizumab Combination I/O in Subjects With HPV16 + Recurrent and/or Metastatic HNSCC

Key facts

Sponsor

PDS Biotechnology Corp.

Principal Investigator

David T Schaaf, MD

PDS Biotechnology Corporation

Intervention

Pembrolizumab (KEYTRUDA®) and PDS0101(combination_product)

Enrollment

95 enrolled

Eligibility

18 years · All sexes

Timeline

2021 – 2025

Study locations (23)

• Marin Cancer Center, Greenbrae, California, United States
• University of California San Francisco, San Francisco, California, United States
• Mayo Clinic, Jacksonville, Florida, United States
• Cleveland Clinic Florida, Weston, Florida, United States
• University of Kentucky Chandler Medical Center - Markey Cancer Center, Lexington, Kentucky, United States
• University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore, Maryland, United States
• University of Michigan, Ann Arbor, Michigan, United States
• Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States
• Mayo Clinic, Rochester, Minnesota, United States
• Atlantic Health, Morristown, New Jersey, United States
• University of North Carolina, Chapel Hill, North Carolina, United States
• Ohio State University, Columbus, Ohio, United States
• Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
• Medical University of South Carolina Hollings Cancer Center, Charleston, South Carolina, United States
• University of Tennessee, Knoxville, Tennessee, United States
• +8 more locations on ClinicalTrials.gov

Collaborators

Merck Sharp & Dohme LLC

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Squamous cell carcinoma of head and neck

Additional recruiting or active studies for the same condition.

• RECRUITINGPHASE3NCT07333274
  Compare Radiotherapy Plus Nimotuzumab Versus Radiotherapy Alone in Platinum-ineligible Patients With Locoregionally Advanced Head and Neck Squamous Cell Carcinoma
  Shandong Cancer Hospital and Institute
• RECRUITINGPHASE3NCT07026474
  Re-Radiochemotherapy and Pembrolizumab vs. Immuno(Chemo)Therapy for Locoregionally Recurrent PD-L1 Positive (CPS≥1) HNSCC
  Universität des Saarlandes
• RECRUITINGPHASE1NCT07182149
  A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors
  Normunity AccelCo, Inc.
• RECRUITINGNANCT07203911
  Surgeon-performed Ultrasound for Real-time Guidance In Oral Cancer Surgeries - A Multicenter Randomized Controlled Trial
  Tobias Todsen
• RECRUITINGNANCT07180901
  Proactive Risk-based Optimization & Notifications for Treatment & Outcomes in Head & Neck Cancer
  Centre hospitalier de l'Université de Montréal (CHUM)
• ACTIVE NOT RECRUITINGEARLY PHASE1NCT07435415
  Local Injection Methylene Blue Combined With Radiation in HNSCC Patients
  China Medical University Hospital
• RECRUITINGPHASE2NCT07088211
  Sacituzumab Tirumotecan and Toripalimab in the First-line Treatment of HNSCC
  Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
• RECRUITINGPHASE2NCT07040956
  A Clinical Trial Comparing Low-Dose RT + Targeted Therapy+ Immunotherapy vs Targeted Therapy+ Immunotherapy Alone as Neoadjuvant Therapy in Operable HNSCC Patients.
  West China Hospital

See all trials for Squamous cell carcinoma of head and neck →